Optimizing the Management of Asthma: The Critical Role of the Pharmacist

Kyle R. Copeland, PharmD
Published Online: Monday, June 23, 2014
Follow Pharmacy_Times:
Supported by an educational grant from Teva Pharmaceuticals.

Optimizing the Management of Asthma: The Critical Role of the Pharmacist

Kyle R. Copeland, PharmD
Clinical Specialist Pharmacist
Parkwest Medical Center
Knoxville, Tennessee
Associate Professor
University of Tennessee College of Pharmacy
South College of Pharmacy
Knoxville, Tennessee

Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty
Kyle R. Copeland, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff—David Heckard; Maryjo Dixon, RPh; Donna Fausak; and Nathalie Harden

Pharmacy Times Editorial Staff
Bea Riemschneider and Kirk McKay

An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial
interests to disclose.


Educational Objectives
Educational Objectives
At the conclusion of this educational activity, participants should be able to:
1. Review current management of asthma, including the most current guideline recommendations, control based on severity and age group, and emerging treatments.
2. Explore the use of diagnostic and patient assessment tools to monitor response to treatment.
3. Discuss the recognition of patients with difficult-to-treat asthma, and options for treatment.
4. Address the pharmacist’s role in patient education and the importance of sustained proper inhaler technique and medication adherence.

Target audience: Pharmacists
Type of activity: Knowledge
Release date: June 20, 2014
Expiration date: June 20, 2016
Estimated time to complete activity: 2.0 hours


Click here to view this activity.
Click here to view this activity.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-14-058-H01-P. The activity is available for CE credit through June 20, 2016.


Related Articles
In a recent phase 2b study, patients with asthma reported reduced exacerbations and improved lung function after receiving dupilumab, an investigational therapy from Sanofi-Aventis and Regeneron Pharmaceuticals Inc.
Latest Issues
$auto_registration$